17 million euro investment planned for Killorglin plant

Fujisawa has announced it`s to invest 17 million euro in expanding its Killorglin pharmaceutical plant. The company which employs 280 people has constructed a 27,000 square ft extension to provide additional production space. This latest announcement shows a growing confidence in the Killorglin facility. The plant in South Kerry is a pharmaceutical finishing plant which makes a drug called prograf, an immunosuppressant which is used to prevent the rejection of transplanted organs. Worldwide distribution of the drug is from Killorglin.The company has grown significantly since it first began operation in 1991. It initially employed 27 people, it currently has a staff of 280 the majority from the high tech sientific sector. Fujisawa employs 8,000 people worldwide and is one of the leading pharmaceutical companies in the Japanese market. Today`s announcement has been welcomed by Minister John O Donohue.